A potential role for GPR55 in the regulation of energy homeostasis.

“G protein-coupled receptor 55 (GPR55) is a putative cannabinoid receptor that is expressed in several tissues involved in regulating energy homeostasis, including the hypothalamus, gastrointestinal tract, pancreas, liver, white adipose and skeletal muscle.

GPR55 has been shown to have a role in cancer and gastrointestinal inflammation, as well as in obesity and type 2 diabetes mellitus (T2DM).

Despite this, the (patho)physiological role of GPR55 in cell dysfunction is still poorly understood, largely because of the limited identification of downstream signalling targets.

Nonetheless, research has suggested that GPR55 modulation would be a useful pharmacological target in metabolically active tissues to improve treatment of diseases such as obesity and T2DM.

Further research is essential to gain a better understanding of the role that this receptor might have in these and other pathophysiological conditions.”

http://www.ncbi.nlm.nih.gov/pubmed/24370891

Chronic administration during early adulthood does not alter the hormonally-dependent disruptive effects of delta-9-tetrahydrocannabinol (Δ9-THC) on complex behavior in female rats.

“This study examined whether chronic Δ9-THC during early adulthood would produce the same hormonally-dependent deficits in learning that are produced by chronic Δ9-THC during adolescence…

no significant effects of chronic treatment and no significant interaction between the chronic treatment and cannabinoid signaling. Thus, acute Δ9-THC produced hormonally-dependent effects on learning and performance behavior, but a period of chronic administration during early adulthood did not alter these effects significantly, which is contrary to what we and others have shown for chronic administration during adolescence.”

http://www.ncbi.nlm.nih.gov/pubmed/24361784

The agonist binding mechanism of human CB2 receptor studied by molecular dynamics simulation, free energy calculation and 3D-QSAR studies.

“CB2-selective agonists have drawn attention in drug discovery, since CB2 becomes a promising target for the treatment of neuropathic pain without psychoactive or other CNS-related side effects…

A combinational exploration of both CoMFA steric and potential contour maps for CB2 affinities and the MD studied interaction modes sheds light on the structural requirements for CB2 agonists and serves as a basis for the design of novel CB2 agonists.”

http://www.ncbi.nlm.nih.gov/pubmed/24358778

Improved Cardiac and Neurologic Outcomes With Postresuscitation Infusion of Cannabinoid Receptor Agonist WIN55, 212-2 Depend on Hypothermia in a Rat Model of Cardiac Arrest*.

“OBJECTIVES: To investigate the mechanisms of improved myocardial and neurological function and survival following IV administration of cannabinoid receptor agonist, WIN55, 212-2 in a rat model of cardiac arrest…

CONCLUSIONS: In a rat model of cardiac arrest, better postresuscitation myocardial function, neurological deficit scores, and longer duration of survival were observed by the pharmacologically induced hypothermia with WIN55, 212-2. The improved outcomes of cardiopulmonary resuscitation following administration of WIN55, 212-2 appeared to be the results from its temperature reduction effects.”

http://www.ncbi.nlm.nih.gov/pubmed/24346544

Selective CB2 receptor activation ameliorates EAE by reducing Th17 differentiation and immune cell accumulation in the CNS.

“CB2, the cannabinoid receptor expressed primarily on hematopoietic cells and activated microglia, mediates the immunoregulatory functions of cannabinoids. The involvement of CB2 in EAE has been demonstrated by using both endogenous and exogenous ligands…

the combined effect on Th17 differentiation and immune cell accumulation into the CNS, emphasize the relevance of CB2 selective ligands as potential therapeutic agents in neuroinflammation.”

http://www.ncbi.nlm.nih.gov/pubmed/24342422

Increase of mesenchymal stem cell migration by Cannabidiol via activation of p42/44 MAPK.

“Migration and differentiation of mesenchymal stem cells (MSCs) are known to be involved in various regenerative processes such as bone healing.

The present study therefore focussed on cannabinoids which have been demonstrated to exhibit tissue healing properties…

Collectively, this study demonstrates CBD to promote the migration of MSCs via activation of the CB2 receptor and inhibition of GPR55 and to induce osteoblastic differentiation. CBD may therefore recruit MSCs to sites of calcifying tissue regeneration and subsequently support bone regeneration via an osteoanabolic action on MSCs.”

http://www.ncbi.nlm.nih.gov/pubmed/24304686

Anti-inflammatory effects of Cannabinoid 2 Receptor activation in endotoxin-induced uveitis.

“CB2 R stimulation has immunomodulatory effects. This study investigated the effects of CB2 R modulation on leukocyte-endothelial adhesion and inflammatory mediator release in experimental endotoxin-induced uveitis (EIU).

Stimulation of CB2 R is anti-inflammatory in a model of acute EIU by a mechanism involving a reduction in NF-κβ, AP-1 and inflammatory mediators.

CB2 R may be a promising drug target for the development of novel ocular anti-inflammatory agents.”

http://www.ncbi.nlm.nih.gov/pubmed/24308861

The cannabinoid receptor type 2 as mediator of mesenchymal stromal cell immunosuppressive properties.

“Recently, the presence of the endocannabinoid system in hematopoietic and neural stem cells has been demonstrated…

In the present study, we have investigated, through a multidisciplinary approach, the involvement of the endocannabinoids in migration, viability and cytokine release of human mesenchymal stromal cells.

We show, for the first time, that cultures of human mesenchymal stromal cells express all of the components of the endocannabinoid system, suggesting a potential role for the cannabinoid CB2 receptor as a mediator of anti-inflammatory properties of human mesenchymal stromal cells, as well as of their survival pathways and their capability to home and migrate towards endocannabinoid sources.”

http://www.ncbi.nlm.nih.gov/pubmed/24312195

Cannabinoids and the endocannabinoid system in lower urinary tract function and dysfunction.

“AIMS: To review knowledge on cannabinoids and the endocannabinoid system in lower urinary tract function and dysfunction.

 

RESULTS AND DISCUSSION:

Components of the endocannabinoid system-cannabinoid (CB) receptor types 1 and 2, anandamide, and fatty acid amide hydrolase (FAAH), which degrades anandamide and related fatty-acid amides-have been located to lower urinary tract tissues of mice, rats, monkeys, and humans. Studies have located CB receptors in urothelium and sensory nerves and FAAH in the urothelium. CB receptor- and FAAH-related activities have also been reported in the lumbosacral spinal cord. Data on supraspinal CB functions in relation to micturition are lacking. Cannabinoids are reported to reduce sensory activity of isolated tissues, cause antihyperalgesia in animal studies of bladder inflammation, affect urodynamics parameters reflecting sensory functions in animals models, and appear to have effects on storage symptoms in humans. FAAH inhibitors have affected sensory bladder functions and reduced bladder overactivity in rat models. Cannabinoids may modify nerve-mediated functions of isolated lower urinary tract tissues.

CONCLUSIONS:

Evidence suggests components of the endocannabinoid system are involved in regulation of bladder function, possibly at several levels of the micturition pathway. It is unclear if either CB receptor has a dominant role in modification of sensory signals or if differences exist at peripheral and central nervous sites. Amplification of endocannabinoid activity by FAAH inhibitors may be an attractive drug target in specific pathways involved in LUTS.”

http://www.ncbi.nlm.nih.gov/pubmed/24285567

Anticancer potential of Magnolia – Science

Cancer related image 

“Anticancer potential of magnolol for lung cancer treatment… Magnolol has been reported to have anticancer property… These data indicate that magnolol is a potential candidate for treating of human lung carcinoma.” http://www.ncbi.nlm.nih.gov/pubmed/21544728

“Magnolol induces apoptosis via caspase-independent pathways in non-small cell lung cancer cells (NSCLC). Magnolol, a hydroxylated biphenyl agent isolated from herbal planet Magnolia officinalis, is a component of traditional Asian herbal teas. It has been reported to have anti-microbial, anti-inflammatory, and anti-cancer activity… The results of this study provided a basis for understanding and developing magnolol as a novel treatment of NSCLC.” http://www.ncbi.nlm.nih.gov/pubmed/23943503

“Magnolol-induced H460 cells death via autophagy but not apoptosis. We have reported that the protective effect of Magnolol on TBHP-induced injury in human nonsmall lung cancer H460 cells is partially via a p53 dependent mechanism… Magnolol induces H460 cells death by autophagy but not apoptotic pathway… Autophagic cells death induction by Magnolol underlines the potential utility of its induction as a new cancer treatment modality.” http://www.ncbi.nlm.nih.gov/pubmed/18254244

“Honokiol Inhibits Non-Small Cell Lung Cancer Cell Migration by Targeting PGE2-Mediated Activation of β-Catenin Signaling… These results indicate that honokiol inhibits non-small cell lung cancer cells migration by targeting PGE2-mediated activation of β-catenin signaling… Thus intervention strategies targeting key signaling molecules of the PGE2-Wnt/β-catenin pathway may represent promising options to inhibit metastasis of lung cancer cells, and may serve as the basis for chemoprevention or therapy of lung cancer in human patients.” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3620279/

“Honokiol inhibits the growth of head and neck squamous cell carcinoma by targeting epidermal growth factor receptor. Here, we report the chemotherapeutic effect of honokiol, a phytochemical fromMagnolia plant, on human head and neck squamous cell carcinoma (HNSCC). Conclusively, honokiol appears to be an attractive bioactive small molecule phytochemical for the management of head and neck cancer which can be used either alone or in combination with other available therapeutic drugs.” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673264/

“Effector mechanism of magnolol-induced apoptosis in human lung squamous carcinoma CH27 cells. Magnolol, an active component isolated from the root and stem bark of Magnolia officinalis, has been reported to exhibit antitumour effects… Magnolol inhibited proliferation of human lung squamous carcinoma CH27 cells at low concentrations, and induced apoptosis at high concentrations…”  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1573650/

“Magnolol, a natural compound, induces apoptosis of SGC-7901 human gastric adenocarcinoma cells via the mitochondrial and PI3K/Akt signaling pathways… Plants are considered as one of the most important sources for the development of anticancer drugs. Magnolol, a natural compound possesses anticancer properties…These findings provide evidence that Magnolol is a promising natural compound for the treatment of gastric cancer and may represent a candidate for in vivo studies of monotherapies or combination antitumor therapies.” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584565/

“Magnolol-Induced Apoptosis in HCT-116 Colon Cancer Cells Is Associated with the AMP-Activated Protein Kinase Signaling Pathway… Magnolol, a hydroxylated biphenyl compound present in Magnolia officinalis, exerts anticancer potential and low toxicity… These findings demonstrate that AMPK mediates the anticancer effects of magnolol through apoptosis in HCT-116 cells.” https://www.jstage.jst.go.jp/article/bpb/35/9/35_b12-00352/_article

“Honokiol in combination with radiation targets Notch signaling to inhibit colon cancer stem cells. ” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3324630/

“Honokiol: a novel natural agent for cancer prevention and therapy. Honokiol is a bioactive natural product derived from Magnolia spp. Recent studies have demonstrated anti-inflammatory, anti-angiogenic, anti-oxidative and anti-cancer properties of honokiol in vitro and in preclinical models.” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663139/

“Honokiol augments the anti-cancer effects of oxaliplatin in colon cancer cells… honokiol can be used in combination with oxaliplatin in the chemotherapy of colon cancer. This combination allows a reduction in oxaliplatin dose, and thereby reduces its adverse effects. It may also enhance the chemotherapeutic effect…”  http://www.ncbi.nlm.nih.gov/pubmed/23786838

“Honokiol Eliminates Human Oral Cancer Stem-Like Cells Accompanied with Suppression of Wnt/β-Catenin Signaling and Apoptosis Induction. Honokiol, an active compound of Magnolia officinalis, exerted many anticancer effects on various types of cancer cells. We explored its effects on the elimination of cancer stem-like side population (SP) cells in human oral squamous cell carcinoma SAS cells… Our findings indicate honokiol may be able to eliminate oral cancer… ” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3638590/

“Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells. We observed that treatment of prostate cancer cells for 24 h with magnolol, a phenolic component extracted from the root and stem bark of the oriental herb Magnolia officinalis, induced apoptotic cell death in a dose- and time-dependent manner… These results suggest that one of the mechanisms of the apoptotic activity of magnolol involves its effect on epidermal growth factor receptor (EGFR)-mediated signaling transduction pathways.” http://www.ncbi.nlm.nih.gov/pubmed/19229860

“Autophagy triggered by magnolol derivative negatively regulates angiogenesis…  These studies, while disclosing the vital role of autophagy in the regulation of angiogenesis, also suggest that the potent modulators of autophagy can lead to the development of effective therapeutics in apoptosis-resistant cancer.” http://www.ncbi.nlm.nih.gov/pubmed/24176847

“Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis. Honokiol, a small-molecule polyphenol isolated from magnolia species, is widely known for its therapeutic potential as an antiinflammatory, antithrombosis, and antioxidant agent, and more recently, for its protective function in the pathogenesis of carcinogenesis… Taken together, these data provide the first in vitro and in vivo evidence of the integral role of the LKB1-AMPK axis in honokiol-mediated inhibition of the invasion and migration of breast cancer cells. In conclusion, honokiol treatment could potentially be a rational therapeutic strategy for breast carcinoma.” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496153/

“Honokiol synergizes chemotherapy drugs in multidrug resistant breast cancer cells via enhanced apoptosis and additional programmed necrotic death… These findings indicate a promising way to circumvent MDR and apoptosis tolerance.” http://www.ncbi.nlm.nih.gov/pubmed/23242346

“Magnolol induces apoptosis in MCF-7 human breast cancer cells through G2/M phase arrest and caspase-independent pathway. Magnolol, a small-molecule hydroxylated biphenol, isolated from the root and stem bark of Magnolia officinalis, has been shown to possess antiproliferative effect on various cancer cell lines. In the current study, we found that magnolol potently inhibited proliferation and induced apoptosis in MCF-7 human breast cancer cells…  Our findings indicated that magnolol induced apoptosis in MCF-7 cells via the intrinsic pathway with release of AIF from mitochondrial and G2/M phase arrest pathway. Therefore, magnolol might be a potential lead compound in the therapy of breast cancer.” http://www.ncbi.nlm.nih.gov/pubmed/24147344

“Screening active anti-breast cancer compounds from Cortex Magnolia officinalis by 2D LC-MS.” http://www.ncbi.nlm.nih.gov/pubmed/23401389

“Magnolol Suppresses Vascular Endothelial Growth Factor-Induced Angiogenesis by Inhibiting Ras-Dependent Mitogen-Activated Protein Kinase and Phosphatidylinositol 3-Kinase/Akt Signaling Pathways. Magnolol, a hydroxylated biphenyl compound isolated from Magnolia officinalis, has been reported to possess anticancer activity. Recent studies have also demonstrated that magnolol inhibits cell growth and induces the apoptosis of cancer cells… these results demonstrate that magnolol is an inhibitor of angiogenesis and suggest that this compound could be a potential candidate in the treatment of angiogenesis-related diseases.” http://www.ncbi.nlm.nih.gov/pubmed/24066970

“Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells… Magnolol isolated from Magnolia officinalis has been reported to exhibit an anticancer activity via elevation of apoptosis… these findings strongly indicate that the anti-agngiogenic activity of magnolol is, at least in part, mediated by suppressing HIF-1α/VEGF-dependent pathways, and suggest that magnolol may be a potential drug for human bladder cancer therapy.” http://www.ncbi.nlm.nih.gov/pubmed/23416116

“Signaling pathway for TNF-alpha-induced MMP-9 expression: mediation through p38 MAP kinase, and inhibition by anti-cancer molecule magnolol in human urinary bladder cancer 5637 cells.” http://www.ncbi.nlm.nih.gov/pubmed/18801463

“Wnt/β-Catenin Signaling Mediates the Antitumor Activity of Magnolol in Colorectal Cancer Cells… In summary, the present study demonstrates that magnolol might be a potential candidate in the development of small molecule inhibitors of Wnt signaling. Therefore, magnolol might be useful for treating sporadic colon cancer cells either alone or in combination with other chemotherapeutic agents.” http://molpharm.aspetjournals.org/content/82/2/168.long

“Targeting apoptosis pathways in cancer with magnolol and honokiol, bioactive constituents of the bark of Magnolia officinalis… Magnolol and honokiol were found to possess anti-tumor activity by targeting the apoptosis pathways, which have been considered as targets for cancer therapies…These breakthrough findings may have important implications for targeted cancer therapy and modern applications of traditional Chinese medicine.” http://www.ncbi.nlm.nih.gov/pubmed/22466367

“Design and synthesis of novel magnolol derivatives as potential antimicrobial and antiproliferative compounds.” http://www.ncbi.nlm.nih.gov/pubmed/22424614

“Effects of magnolol on UVB-induced skin cancer development in mice and its possible mechanism of action. Magnolol, a plant lignan isolated from the bark and seed cones of Magnolia officinalis, has been shown to have chemopreventive effects on chemically-induced skin cancer development… Magnolol pretreatments prevent UVB-induced skin cancer development by enhancing apoptosis, causing cell cycle arrest at G2/M phase, and affecting various signaling pathways. Magnolol could be a potentially safe and potent anticarcinogenic agent against skin cancer.” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234292/

“Time and dose-response effects of honokiol on UVB-induced skin cancer development…Honokiol has shown chemopreventive effects in chemically-induced and UVB-induced skin cancer… . Honokiol prevents UVB-induced skin cancer in a dose-dependent manner. Honokiol can be an effective chemopreventive agent against skin cancer.” http://www.ncbi.nlm.nih.gov/pubmed/22890204

“Honokiol, a chemopreventive agent against skin cancer, induces cell cycle arrest and apoptosis in human epidermoid A431 cells. Honokiol is a plant lignan isolated from bark and seed cones of Magnolia officinalis. Recent studies from our laboratory indicated that honokiol pretreatment decreased ultraviolet B-induced skin cancer development in SKH-1 mice…These findings indicate that honokiol provides its effects in squamous carcinoma cells by inducing cell cycle arrest at G0/G1 phase and apoptosis.” http://www.ncbi.nlm.nih.gov/pubmed/21908486

“Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-kappaB activation pathway… Recent reports have indicated that honokiol can induce apoptosis, suppress tumor growth, and inhibit angiogenesis.” http://mcr.aacrjournals.org/content/4/9/621.long

“Magnolol induces apoptosis via activation of both mitochondrial and death receptor pathways in A375-S2 cells. Magnolol inhibited proliferation of human malignant melanoma A375-S2 cells…  our results indicate that magnolol induces apoptosis by activation of both mitochondrial and death receptor pathways in A375-S2 cells.” http://www.ncbi.nlm.nih.gov/pubmed/20162409

“Honokiol induces cytotoxic and cytostatic effects in malignant melanoma cancer cells… Honokiol is highly effective in inhibiting melanoma cancer cells by attenuating AKT/mammalian target of rapamycin and Notch signaling. These studies warrant further clinical evaluation for honokiol alone or with present chemotherapeutic regimens for the treatment of melanomas.” http://www.ncbi.nlm.nih.gov/pubmed/23231930

“Studies on inhibitors of skin tumor promotion, IX. Neolignans from Magnolia officinalis… This investigation indicates that these neolignans and the extract might be valuable antitumor promoters.” http://www.ncbi.nlm.nih.gov/pubmed/1659613

“Inhibitory effect of magnolol on TPA-induced skin inflammation and tumor promotion in mice. Magnolol has been reported to have an anti-inflammatory and antitumor effect in vitro and in vivo…  All these results revealed that magnolol is an effective antitumor agent…” http://www.ncbi.nlm.nih.gov/pubmed/20218615

“Magnolol down-regulates HER2 gene expression, leading to inhibition of HER2-mediated metastatic potential in ovarian cancer cells… Magnolol has been reported to exhibit anti-tumor activities…  These results provide a novel mechanism to explain the anti-cancer effect of magnolol.” http://www.ncbi.nlm.nih.gov/pubmed/21757288

“Magnolol Suppresses Metastasis via Inhibition of Invasion, Migration, and Matrix Metalloproteinase-2/-9 Activities in PC-3 Human Prostate Carcinoma Cells. Magnolol, a hydroxylated biphenyl compound isolated from the root and stem bark of Magnolia officinalis, has been reported to have anticancer activity… These results demonstrate the antimetastatic properties of magnolol in inhibiting the adhesion, invasion, and migration of PC-3 human prostate cancer cells.” https://www.jstage.jst.go.jp/article/bbb/74/5/74_90785/_article

“Magnolol inhibits human glioblastoma cell proliferation through upregulation of p21/Cip1. Previously, we demonstrated that magnolol isolated from the bark of Magnolia officinalis has anticancer activity in colon, hepatoma, and leukemia cell lines. In this study, we show that magnolol concentration dependently decreased the cell number in a cultured human glioblastoma cancer cell line…  Our findings suggest the potential applications of magnolol in the treatment of human brain cancers.” http://www.ncbi.nlm.nih.gov/pubmed/19645506

“Mechanisms for the magnolol-induced cell death of CGTH W-2 thyroid carcinoma cells. Magnolol, a substance purified from the bark of Magnolia officialis, inhibits cell proliferation and induces apoptosis in a variety of cancer cells. The aim of this study was to study the effects of magnolol on CGTH W-2 thyroid carcinoma cells…  These results show that magnolol initiates apoptosis via the cytochrome-c/caspase 3/PARP/AIF and PTEN/Akt/caspase 9/PARP pathways and necrosis via PARP activation.” http://www.ncbi.nlm.nih.gov/pubmed/17390340

“In vitro anti-mutagenic effect of magnolol against direct and indirect mutagens. Magnolol, a component of the bark of Magnolia obovata, has been reported to possess various biological activities, such as anti-carcinogenicity, anti-promotion activity and anti-oxidative activity. These findings suggest potential for this compound in cancer chemoprevention.” http://www.ncbi.nlm.nih.gov/pubmed/16884943

“Molecular mechanisms of apoptosis induced by magnolol in colon and liver cancer cells. Magnolol has been reported to have anticancer activity.” http://www.ncbi.nlm.nih.gov/pubmed/11746819

“Magnolol suppresses proliferation of cultured human colon and liver cancer cells by inhibiting DNA synthesis and activating apoptosis. Magnolol, a hydroxylated biphenyl compound isolated from the Chinese herb Hou p’u of Magnolia officinalis, has been reported to have anti-cancer activity…  These findings demonstrate for the first time that magnolol can inhibit the proliferation of tumor cells in vitro and in vivo.” http://www.ncbi.nlm.nih.gov/pubmed/11813258

“Inhibitory effect of magnolol on tumour metastasis in mice. It has previously been reported that magnolol, a phenolic compound isolated from Magnolia obovata, inhibited tumour cell invasion in vitro. The purpose of this study was to investigate the antimetastatic effect of magnolol on tumour metastasis in vivo… These data from the in vivo experiments suggest that magnolol possesses strong antimetastatic ability and that it may be a lead compound for drug development. The antimetastatic action of magnolol is considered to be due to its ability to inhibit tumour cell invasion.” http://www.ncbi.nlm.nih.gov/pubmed/13680828

“Therapeutic applications of compounds in the Magnolia family… anti-cancer, anti-stress, anti-anxiety, anti-depressant, anti-oxidant, anti-inflammatory and hepatoprotective…” http://www.ncbi.nlm.nih.gov/pubmed/21277893

“Magnolia Extract Fights Difficult-to-Treat Cancers” http://www.empowher.com/cancer/content/magnolia-extract-fights-difficult-treat-cancers

“Magnolia dealbata seeds extract exert cytotoxic and chemopreventive effects on MDA-MB231 breast cancer cells. Magnolia dealbata Zucc (Magnoliaceae), a Mexican endemic species, is used for the empirical treatment of cancer. Objective: To evaluate the cytotoxic and cancer chemopreventive effects of an ethanol extract of Magnolia dealbata seeds (MDE)… Conclusions: MDE exerts cytotoxic, apoptotic and chemopreventive activities on MDA-MB231 human cancer cells.”  http://www.ncbi.nlm.nih.gov/pubmed/24400594